BUZZ-Transition Therapeutics Inc: Alzheimer drug effective in sub-group
** Canadian drug developer's shares up nearly 17 pct premarket
** Company says analysis shows the drug ELND005 was effective in reducing severe agitation and aggression in Alzheimer's patients
** Large study in June failed to hit main goal of reducing moderate to severe agitation and aggression in patients, pushing shares down as much as 20 pct that day
** Company says to discuss potential late-stage study with the U.S. FDA
** Up to Wednesday's close, stock had fallen about 20 pct since the company reported top-line data from the study
© Thomson Reuters 2017 All rights reserved.